Literature DB >> 21303371

Fukuoka-1 strain of transmissible spongiform encephalopathy agent infects murine bone marrow-derived cells with features of mesenchymal stem cells.

Larisa Cervenakova1, Sergey Akimov, Irina Vasilyeva, Oksana Yakovleva, Carroll McKenzie, Juraj Cervenak, Pedro Piccardo, David M Asher.   

Abstract

BACKGROUND: The possible risk of iatrogenic transmissible spongiform encephalopathies (TSEs, prion diseases) from transplantation of marrow-derived mesenchymal stem cells (MSCs) is uncertain. While most cell lines resist infection, a few propagate TSE agents. STUDY DESIGN AND METHODS: We generated MSC-like (MSC-L) cell cultures from bone marrow (BM) of mice inoculated with the human-derived Fukuoka-1 (Fu) strain of TSE agent. Cultured cells were characterized for various markers and cellular prion protein (PrP(C) ) by fluorescence-activated cell sorting and for PrP(C) and its pathologic TSE-associated form (PrP(TSE) ) by Western blotting (WB). Cell cultures were tested for their susceptibility to infection with Fu in vitro. The infectivity of one Fu-infected cell culture was assayed in mice.
RESULTS: BM cells from Fu-infected mice expressed neither PrP(C) nor PrP(TSE) after 3 days in culture as demonstrated by WB. Cells adherent to plastic and maintained under two different culture conditions became spontaneously immortalized and began to express PrP(C) at about the same time. One culture became transformed shortly after exposure to Fu in vitro and remained persistently infected, continuously generating PrP(TSE) through multiple passages; the infectivity of cultured cells was confirmed by intracerebral inoculation of lysates into mice. Both persistently TSE-infected and uninfected cells expressed a number of typical MSC markers.
CONCLUSION: BM-derived MSC-L cells of mice became persistently infected with the Fu agent under certain conditions in culture-conditions that differ substantially from those currently used to develop investigational human stem cell therapies.
© 2011 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303371      PMCID: PMC3112470          DOI: 10.1111/j.1537-2995.2010.03041.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  69 in total

Review 1.  Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease.

Authors:  P Brown; L Cervenáková; H Diringer
Journal:  J Lab Clin Med       Date:  2001-01

2.  Comparative study of stromal cell lines derived from embryonic, fetal, and postnatal mouse blood-forming tissues.

Authors:  Pierre Charbord; Robert Oostendorp; Wenxin Pang; Olivier Hérault; Frederic Noel; Takashi Tsuji; Elaine Dzierzak; Bruno Péault
Journal:  Exp Hematol       Date:  2002-10       Impact factor: 3.084

3.  Molecular basis of scrapie strain glycoform variation.

Authors:  Ina Vorberg; Suzette A Priola
Journal:  J Biol Chem       Date:  2002-07-23       Impact factor: 5.157

4.  Prion diseases are efficiently transmitted by blood transfusion in sheep.

Authors:  Fiona Houston; Sandra McCutcheon; Wilfred Goldmann; Angela Chong; James Foster; Silvia Sisó; Lorenzo González; Martin Jeffrey; Nora Hunter
Journal:  Blood       Date:  2008-07-22       Impact factor: 22.113

5.  Transmission of prion diseases by blood transfusion.

Authors:  Nora Hunter; James Foster; Angela Chong; Sandra McCutcheon; David Parnham; Samantha Eaton; Calum MacKenzie; Fiona Houston
Journal:  J Gen Virol       Date:  2002-11       Impact factor: 3.891

6.  Iatrogenic Creutzfeldt-Jakob disease: the waning of an era.

Authors:  Paul Brown; Jean-Philippe Brandel; Michael Preece; Michael Preese; Takeshi Sato
Journal:  Neurology       Date:  2006-07-19       Impact factor: 9.910

7.  Transmission of BSE by blood transfusion in sheep.

Authors:  F Houston; J D Foster; A Chong; N Hunter; C J Bostock
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

8.  Strain-specific viral properties of variant Creutzfeldt-Jakob disease (vCJD) are encoded by the agent and not by host prion protein.

Authors:  Laura Manuelidis; Ying Liu; Brian Mullins
Journal:  J Cell Biochem       Date:  2009-02-01       Impact factor: 4.429

9.  Bone marrow stroma cells are susceptible to prion infection.

Authors:  Yuka Takakura; Naohiro Yamaguchi; Takehiro Nakagaki; Katsuya Satoh; Jun-ichi Kira; Noriyuki Nishida
Journal:  Biochem Biophys Res Commun       Date:  2008-10-29       Impact factor: 3.575

10.  Persistent propagation of variant Creutzfeldt-Jakob disease agent in murine spleen stromal cell culture with features of mesenchymal stem cells.

Authors:  Sergey Akimov; Oksana Yakovleva; Irina Vasilyeva; Carroll McKenzie; Larisa Cervenakova
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

View more
  12 in total

1.  First demonstration of transmissible spongiform encephalopathy-associated prion protein (PrPTSE) in extracellular vesicles from plasma of mice infected with mouse-adapted variant Creutzfeldt-Jakob disease by in vitro amplification.

Authors:  Paula Saá; Oksana Yakovleva; Jorge de Castro; Irina Vasilyeva; Silvia H De Paoli; Jan Simak; Larisa Cervenakova
Journal:  J Biol Chem       Date:  2014-08-25       Impact factor: 5.157

2.  Squirrel monkeys (Saimiri sciureus) infected with the agent of bovine spongiform encephalopathy develop tau pathology.

Authors:  P Piccardo; J Cervenak; O Yakovleva; L Gregori; K Pomeroy; A Cook; F S Muhammad; T Seuberlich; L Cervenakova; D M Asher
Journal:  J Comp Pathol       Date:  2011-10-20       Impact factor: 1.311

Review 3.  Cellular aspects of prion replication in vitro.

Authors:  Andrea Grassmann; Hanna Wolf; Julia Hofmann; James Graham; Ina Vorberg
Journal:  Viruses       Date:  2013-01-22       Impact factor: 5.048

4.  Transcriptomic analysis brings new insight into the biological role of the prion protein during mouse embryogenesis.

Authors:  Manal Khalifé; Rachel Young; Bruno Passet; Sophie Halliez; Marthe Vilotte; Florence Jaffrezic; Sylvain Marthey; Vincent Béringue; Daniel Vaiman; Fabienne Le Provost; Hubert Laude; Jean-Luc Vilotte
Journal:  PLoS One       Date:  2011-08-15       Impact factor: 3.240

5.  Candidate cell substrates, vaccine production, and transmissible spongiform encephalopathies.

Authors:  Pedro Piccardo; Larisa Cervenakova; Irina Vasilyeva; Oksana Yakovleva; Igor Bacik; Juraj Cervenak; Carroll McKenzie; Lubica Kurillova; Luisa Gregori; Kitty Pomeroy; David M Asher
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

6.  A robust and reproducible animal serum-free culture method for clinical-grade bone marrow-derived mesenchymal stromal cells.

Authors:  Anita Laitinen; Sofia Oja; Lotta Kilpinen; Tanja Kaartinen; Johanna Möller; Saara Laitinen; Matti Korhonen; Johanna Nystedt
Journal:  Cytotechnology       Date:  2015-03-17       Impact factor: 2.058

7.  Effect of Scrapie Prion Infection in Ovine Bone Marrow-Derived Mesenchymal Stem Cells and Ovine Mesenchymal Stem Cell-Derived Neurons.

Authors:  Laura García-Mendívil; Diego R Mediano; Adelaida Hernaiz; David Sanz-Rubio; Francisco J Vázquez; Belén Marín; Óscar López-Pérez; Alicia Otero; Juan J Badiola; Pilar Zaragoza; Laura Ordovás; Rosa Bolea; Inmaculada Martín-Burriel
Journal:  Animals (Basel)       Date:  2021-04-15       Impact factor: 2.752

Review 8.  From Cell Culture to Organoids-Model Systems for Investigating Prion Strain Characteristics.

Authors:  Hailey Pineau; Valerie L Sim
Journal:  Biomolecules       Date:  2021-01-14

Review 9.  Review of the potential of mesenchymal stem cells for the treatment of infectious diseases.

Authors:  Amit Sharma; Anuja Chakraborty; Bithiah Grace Jaganathan
Journal:  World J Stem Cells       Date:  2021-06-26       Impact factor: 5.326

10.  Osteogenic differentiation of mesenchymal stromal cells in two-dimensional and three-dimensional cultures without animal serum.

Authors:  Eeva Castrén; Tarvo Sillat; Sofia Oja; Ariel Noro; Anita Laitinen; Yrjö T Konttinen; Petri Lehenkari; Mika Hukkanen; Matti Korhonen
Journal:  Stem Cell Res Ther       Date:  2015-09-07       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.